Fernando Cruz-Guilloty
Director & Lead, Oncology & Precision Medicine & Diagnostics Johnson & Johnson
Fernando Cruz-Guilloty, is the Director, Oncology – Precision Medicine & Diagnostics at Janssen R&D. As the Amivantamab Franchise Lead, Fernando oversees the overarching Diagnostics (Dx) strategy for the Amivantamab/Rybrevant (EGFR-MET bi-specific Ab) program in biomarker-selected populations of Non-Small Cell Lung Cancer (NSCLC) and other solid tumors, including CRC and HNSCC.
He collaborates with key stakeholders, develops and executes precision medicine strategies to enable registration of pharmaceutical assets, leading a high-performing cross-functional team.
Seminars
Friday 19th March 2027
Panel Discussion: Choosing the Right Diagnostic Partner for the Right Study to Deliver Regulatory-Grade Liquid Biopsy Data
3:00 pm
- Matching assay type, sensitivity and turnaround to the study question, from patient selection and enrichment to response monitoring and MRD
- Evaluating vendors on analytical validation, quality systems and regulatory track record, so data stands up to agency scrutiny
- Structuring the sponsor and vendor relationship early, from contracting and sample logistics to bridging plans if the assay changes mid-program
